Merck and Siemens have signed a new Memorandum of Understanding (MoU) to extend their strategic partnership, aiming to accelerate digital transformation in the life sciences industry. The collaboration will integrate Siemens’ Xcelerator platform with Merck’s life sciences portfolio to deliver end-to-end digital workflows, connecting drug discovery, development, and manufacturing.
The initiative focuses on combining automation, AI, and data-driven tools to simplify complex scientific processes and enable faster, more efficient drug development. This MoU marks the first joint application of technology Siemens acquired through its Dotmatics acquisition in July 2025, with initial pilot projects integrating Merck’s AI tools into Luma, Siemens’ Scientific Intelligence Platform. This integration will give scientists a unified environment to order products and immediately access digital tools and insights for data-driven decisions.
Future projects will include co-developing smarter data management systems, intuitive digital interfaces, and exploring digital marketplaces that offer streamlined access to complementary technologies. By leveraging their combined strengths, the two companies aim to address challenges such as rising drug development costs and workflow inefficiencies.
Leave a comment